Efficacy
PD, tumor
CPS, DISEASE, TUMOR
Objective response was observed in 12 patients and ORR was 57.1% (95% CI 34.0–78.2); 3 (14.3%) patients achieved CR, and 9 (42.9%) achieved PR as their best overall response assessed by IRRC as per RECIST version 1.1 (Objective response rate and disease control rate by IRRC.All values are shown as n (%).NE, non-evaluable; PD, progressive disease.ORR was defined as the proportion of patients achieving CR or PR.DCR was defined as the proportion of patients achieving CR, PR, or SD.Antitumor activity of serplulimab in the FAS. The median DOR was not reached (NR) (95% CI 4.1–NR months; Kaplan–Meier estimates of response duration and survival in the FAS. Investigator assessments as per RECIST version 1.1 on the tumor responses are presented in IRCC-assessed ORR stratified by CPS is presented in 